Eikon Therapeutics, Inc. filed a Form 8-K with the SEC on August 14, 2026, disclosing that the company updated its corporate presentation on August 13, 2026, under Regulation FD.

Key Highlights

  • Event date: The corporate presentation was updated on August 13, 2026.
  • Disclosure item: The filing is made under Item 7.01, Regulation FD Disclosure.
  • Exhibit furnished: The updated presentation is furnished as Exhibit 99.1 and incorporated by reference into the filing.
  • Filing status: The information in Item 7.01, including Exhibit 99.1, is "furnished" and not deemed "filed" for purposes of Section 18 of the Exchange Act.
  • Signatory: The report was signed by Alfred Bowie, Ph.D., Chief Financial Officer of Eikon Therapeutics, Inc.

Eikon Therapeutics Furnishes Revised Investor Presentation Under Regulation FD

Eikon Therapeutics, Inc. (NASDAQ:EIKN), a Delaware-incorporated biopharmaceutical company headquartered at 230 Harriet Tubman Way, Millbrae, California 94030, disclosed on August 13, 2026, that it updated its corporate presentation. According to the filing, the updated presentation is furnished as Exhibit 99.1 to the Current Report on Form 8-K.

The company disclosed that the information in Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The filing further states that the information "shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing."

Eikon Therapeutics noted in the filing that it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The registrant has not elected to use the extended transition period for complying with new or revised financial accounting standards. The filing was signed by Chief Financial Officer Alfred Bowie, Ph.D.

What Was Disclosed

Eikon Therapeutics filed an 8-K to furnish an updated corporate presentation under Regulation FD. The presentation is attached as Exhibit 99.1 and carries furnished-only status, limiting its incorporation by reference into other filings.